Ocular Regulatory T Cells Distinguish Monophasic from Recurrent Autoimmune Uveitis

Yan Ke, Guomin Jiang, Deming Sun, Henry J. Kaplan, and Hui Shao

PURPOSE. To determine whether CD4⁺CD25⁺ T-regulatory cells (Tregs) from the eyes of rats with recurrent (r) experimental autoimmune uveitis (EAU) were less efficient in suppressing intraocular inflammation than those from rats with monophasic (m) disease (m-EAU).

METHODS. m-EAU and r-EAU were induced in Lewis rats by immunization with R16 or by adoptive transfer of R16-specific T cells, respectively. Ocular CD4⁺CD25⁺ Tregs were separated from CD4⁺CD25⁻ T-effector cells, and the inhibitory functions of Tregs were determined. Aqueous humor (AqH) from m-EAU and r-EAU was collected and studied for its ability to enhance ocular Treg function.

RESULTS. The authors found that the number of ocular CD4⁺CD25⁺ (Tregs) increased in the eye during resolution of the first acute attack of intraocular inflammation in m-EAU and r-EAU. However, the suppressor function of these cells was weaker in r-EAU. The suppressor function of ocular Tregs in r-EAU was enhanced by incubation with AqH from animals recovering from m-EAU. Moreover, the weaker suppressor function of ocular Tregs in r-EAU correlated with low or undetectable levels of IL-10 in the AqH and was reversed by the addition of IL-10 to the AqH. Finally, the transfer of ocular Tregs from animals with m-EAU converted r-EAU to a monophasic disease.

CONCLUSIONS. This study demonstrated that although a number of mechanisms may contribute to the recurrence of intraocular inflammation, dysregulation and malfunction of Tregs in the eye are important factors in disease recurrence. (Invest Ophthalmol Vis Sci. 2008;49:5999–6007) DOI:10.1167/iovs.07-1468

Three patterns of autoimmune (idiopathic) uveitis are seen in humans—monophasic, recurrent, and chronic. Chronic and recurrent uveitis are difficult to treat and they account for approximately 10% of legal blindness in the Western world.1 To understand the mechanisms that result in the natural resolution of monophasic uveitis and, thus, to identify optimal therapeutic strategies for recurrent or chronic uveitis, we previously generated experimental animal models of autoimmune uveitis with characteristics of the human disease.2–4 The major pathogenic events in experimental autoimmune uveitis (EAU) are initiated by the activation of T cells reactive with retinal antigens, such as interphotoreceptor retinoid-binding protein (IRBP).5–8 Activated T cells have an increased ability to enter the target organ and to produce cytokines and chemokines to recruit other inflammatory cells that result in retinal tissue damage. Immunization with the immunodominant 1177–1191 peptide (R16) of IRBP results in monophasic disease in the Lewis rat; intraocular inflammation appears on day 8, lasts for 2 weeks, and spontaneously resolves. In contrast, the adoptive transfer of R16-specific T cells in Lewis rats results in recurrent disease that starts on day 4, with repeated recurrences for the next 2 to 3 months. These two models provide us with useful tools for studying the regulation of pathogenic effector T cells in vivo.

A number of mechanisms are likely to contribute to recovery from autoimmune disease, including uveitis.8–10 Recent studies have demonstrated that among CD4 T cells, a subset expressing CD25 has strong suppressor activity.11,12 These naturally arising CD4⁺CD25⁺ regulatory T cells (Tregs) are powerful inhibitors of T-cell activation in vivo and in vitro, acting partially through IL-10 or transforming growth factor β (TGF-β).13,14; they also contribute to the maintenance of immunologic self-tolerance and negative control of various immune responses. Their depletion or alteration of function leads to the development of autoimmune disease in otherwise healthy animals.15

The eye is the prototypic immunoprivileged organ. The ability of the ocular microenvironment, especially the aqueous humor (AqH),16 to suppress immune effector responses and inflammation is believed to be important to the existence of ocular immune privilege.16–18 Normal AqH displays many immunosuppressive and anti-inflammatory properties in vitro. With regard to adaptive immunity, AqH suppresses T-cell activation after ligation of the T-cell receptor (TCR) by antigen, inhibiting the proliferation of T-effector cells and the secretion of IFN-γ.17 It also alters the functional program of TCR ligation-activated, primed T cells, converting the cells to TGF-β-producing regulatory cells.19 Numerous immunomodulatory factors, such as TGF-β,20,21 α-melanocyte-stimulating hormone,22 vasoactive intestinal peptide,23 calcitonin gene-related peptide,24 macrophage migration inhibitory factor,25 and IL-10,26 account for the immunosuppressive properties of AqH. This study provides evidence that Treg cells mediate spontaneous recovery from an active disease process in the target organ.

MATERIALS AND METHODS

Animals and Reagents

Pathogen-free female Lewis rats (5–6 weeks old) were purchased from Harlan Sprague–Dawley (Indianapolis, IN) and were housed and maintained at the animal facilities of the University of Louisville (Louisville, KY).

All animal studies conformed to the ARVO Statement on the Use of Animals in Ophthalmic and Vision Research. Institutional approval was obtained, and institutional guidelines regarding animal experimentation were followed. Bovine IRBP peptide R16 (residues 1177–1191, from the Department of Ophthalmology and Visual Sciences, Kentucky Lions Eye Center, University of Louisville, Louisville, Kentucky.

Supported in part by National Institutes of Health Grants EY12974 and EY14599, Vision Research Infrastructure Development Grant R24 EYO15636, a Research to Prevent Blindness Career Development Award (HS), and the Commonwealth of Kentucky Research Challenge Trust Fund (HJK).

Submitted for publication November 14, 2007; revised February 7, and April 8 and 24, 2008; accepted July 27, 2008.

Disclosure: Y. Ke, None; G. Jiang, None; D. Sun, None; H.J. Kaplan, None; H. Shao, None.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked ‘advertisement’ in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Corresponding author: Hui Shao, Department of Ophthalmology and Visual Sciences, Kentucky Lions Eye Center, University of Louisville, 301 E. Muhammad Ali Boulevard, Louisville, KY 40202; htshtao@louisville.edu.
ADGSSWEGVGVVPDV was synthesized by Sigma-Aldrich (St. Louis, MO).

Animal Model of EAU

The induction of uveitis in Lewis rats by immunization with R16 has been described previously.2,3 Briefly, the rats were immunized subcutaneously with 200 μL of an emulsion containing 50 μg R16 and 500 μg Mycobacterium tuberculosis H37Ra (Difco, Detroit, MI) in incomplete Freund adjuvant (Sigma, St. Louis, MO), distributed over six spots on the tail base and flank.

For induction of uveitis by adoptive transfer of R16-specific T cells,3 naive Lewis rats were injected with in vitro–restimulated R16-specific T cells prepared from rats with uveitis and were examined daily by slit lamp biomicroscopy for clinical signs of uveitis.

Intensity of uveitis was scored blind on an arbitrary scale of 0 to 4,2,3 with 0 representing no disease, 1 representing engorged blood vessels in the iris and an abnormal pupil configuration, 2 representing a hazy anterior chamber, 3 representing a moderately opaque anterior chamber with the pupil still visible, and 4 representing an opaque anterior chamber, obscured pupil, and, frequently, proptosis.

Inflammation in the eye was confirmed by histopathologic examination. Many inflammatory cells, together with a disorganized retinal architecture, retinal detachment, and photoreceptor cell damage, were seen in the anterior and posterior chambers.

Aqueous Humor Collection

Aqueous humor was collected from both eyes by an anterior chamber puncture (20 μL/rat) using a 30-gauge needle under a surgical microscope and was stored immediately in a −80°C freezer until use. The concentration of IL-10 in the AqH was measured by ELISA (rat IL-10 ELISA kit; R&D Systems, Minneapolis, MN). To modulate Treg function in vitro, the AqH was used after the addition of monoclonal antibodies (mAbs) of anti–IL-10 (1 μg/mL; R&D Systems), TGF-β (25 μg/mL; R&D Systems), or an isotype control or after the addition of recombinant rat IL-10 (25 ng/mL; R&D Systems).

Preparation of R16-Specific T Cells

R16-specific T cells were isolated from R16-immunized Lewis rats using previously described methods for generating antigen-specific T cells.2,3 T cells were isolated from lymph node cells or spleen cells 10 days postimmunization (p.i.) by passage through a nylon wool column. The cells (1 × 10⁶) were stimulated for 2 days with 20 μg/mL R16 in 2 mL medium in a six-well plate (Costar, Cambridge, MA) in the presence of 1 × 10⁶ irradiated syngeneic spleen cells as antigen-presenting cells (APCs). Then activated lymphoblasts were isolated by gradient centrifugation (Lymphoprep; Robbins Scientific, Mountain View, CA) and cultured in RPMI 1640 medium (Mediatech, Herndon, VA) supple-
ental with 15% IL-2-containing medium (supernatant from Con-A-stimulated rat spleen cells).

**Isolation of the CD4$^+$CD25$^+$ T-Cell Subset**

Monoclonal antibodies OX6 (mouse anti–rat major histocompatibility complex [MHC class II]), OX8 (mouse anti–rat CD8), OX12 (mouse anti–rat kappa light chain), NKR-P1a (CD161a), and OX39 (mouse anti–rat CD25), used for the purification of T-cell subpopulations and for flow cytometry, were purchased from BD Biosciences (La Jolla, CA). Rat CD4$^+$ T cells were purified from spleen or eye cells by the removal of B cells, CD8 T cells, class II-positive cells, and NK cells using a cocktail of OX-12, OX8, OX6, and NKR-P1a and a MACS magnetic column. Briefly, spleen or eye cells were shaken for 30 minutes in ice with the mAb cocktail, then for 15 minutes at 4°C with anti-mouse IgG microbeads. The cells were then separated into bound and nonbound cells on a separator column (auto-MACS; Miltenyi Biotec Inc., Auburn, CA) that was washed with 15 mL medium according to the manufacturer’s protocol, and the flow-through fraction containing CD4$^+$ enriched cells was collected. CD4$^+$CD25$^+$ T cells were enriched by binding to anti-PE magnetic beads after labeling with PE-conjugated OX-39 mAb; the CD4$^+$CD25$^-$depleted cells were designated as CD4$^+$CD25$^+$ T cells. The purity of the isolated cell fraction was determined by flow cytometric analysis using FITC-conjugated anti-CD4 antibodies and PE-conjugated antibodies directed against the TCR or CD25. *Purity of CD4$^+$CD25$^+$ cells was routinely above 98% for spleen cells and above 85% for ocular cells.

**Immunofluorescence Flow Cytometry**

Aliquots of 2 × 10$^5$ cells were double stained with combinations of FITC- or PE-conjugated mAbs against rat αβ TCR (R73), CD4, CD25, IL-10, or Foxp3 (all from BD Biosciences). For intracellular staining, the cells were incubated for 30 minutes at 4°C with anti–CD4 or isotype control antibodies, fixed overnight with 1 mL fixation buffer (Fix and Perm Cell Permeabilization Kit; eBioscience, San Diego, CA), washed, and incubated for 30 minutes at 4°C with anti–rat-Foxp3 or with anti–rat IL-10 antibodies. Data collection and analysis were performed on a flow cytometer (FACSCalibur; BD Biosciences) using flow cytometry software (CellQuest; BD Biosciences).

**Proliferation Assay**

R16-specific T cells (4 × 10$^5$ cells/well) were cultured at 37°C for 48 hours in 96-well microtiter plates with or without R16 in the presence of 1 × 10$^5$ APCs in a total volume of 200 μL. [3H]-Thymidine was added to each culture for the last 8 hours, and incorporation was assessed using a microplate scintillation counter (Packard Instruments, Meriden, CT). For the in vitro suppression assay, CD4$^+$CD25$^+$ T cells were used as responder cells because they gave a stronger response than total unfractionated T cells. Responder T cells (4 × 10$^5$ cells/well) were prepared on day 9 from rats immunized with R16 and were stimulated for 48 hours with R16 (10 μg/mL) and APCs in the presence or absence of various numbers of CD4$^+$CD25$^+$ Tregs cells. Tregs pretreated with AaH and washed before coculture with R16-specific effector T cells. The proliferative response was expressed as mean ± SD cpm of triplicate determinations.

**Examination of Pathologic Findings**

Inflammation of the eye was confirmed by histopathology. Whole eyes were collected, immersed for 1 hour in 4% phosphate-buffered glutaraldehyde, and transferred to 10% phosphate-buffered formaldehyde until processed. The fixed and dehydrated tissue was embedded in methacrylate, and 5-μm sections were cut through the papillary-optic nerve plane and stained with hematoxylin and eosin. Presence or absence of disease was evaluated blind by examining six sections cut at different levels for each eye. Severity of EAU was scored on a scale of 0 (no disease) to 4 (maximum disease) in half-point increments, as described previously.

**Isolation of Cells from Inflamed Eyes**

After perfusion of the anesthetized rat with PBS on the indicated day after immunization or injection of T cells, the eyes were collected, and a cell suspension was prepared by digestion for 10 minutes at 37°C with collagenase (1 mg/mL) and DNase (100 μg/mL) in RPMI 1640, followed by gradient centrifugation on 25% Percoll and subsequent ficoll separation. Then the cells were washed and resuspended in staining buffer (PBS containing 3% FCS and 0.1% sodium azide) for antibody staining. To identify regulatory T cells in the eye, mouse TCR or CD25. Purity of CD4$^+$ T cells was determined by flow cytometric analysis using FITC-conjugated anti-TCR (R73), CD4, CD25, IL-10, or Foxp3 (all from BD Biosciences). For intracellular staining, the cells were incubated for 30 minutes at 4°C with anti–CD4 or isotype control antibodies, fixed overnight with 1 mL fixation buffer (Fix and Perm Cell Permeabilization Kit; eBioscience, San Diego, CA), washed, and incubated for 30 minutes at 4°C with anti–rat-Foxp3 or with anti–rat IL-10 antibodies. Data collection and analysis were performed on a flow cytometer (FACSCalibur; BD Biosciences) using flow cytometry software (CellQuest; BD Biosciences).
anti-rat mAbs against TCR (for T cells), CD4, CD25, or Foxp3 were used for staining, and the cells were analyzed by flow cytometry.

RESULTS

Accumulation of CD4\(^+\)CD25\(^+\) Cells within the Eye Correlates with Resolution of the First Acute Attack of the Disease in Both m-EAU and r-EAU

After immunization or in response to tissue inflammation, antigen-specific Tregs have been shown to expand or accumulate in draining lymph nodes\(^{29-33}\) and at the site of inflammation.\(^{34}\) We found that during m-EAU induced by immunization with R16 (Fig. 1A), there was a marked increase in the CD4\(^+\) cells expressing CD25\(^+\) in the eye as intraocular inflammation evolved from the peak of disease (day 13) to recovery (day 16; Fig. 1B, left). In contrast, the proportion of CD4\(^+\)CD25\(^+\) cells in the spleen remained fairly constant throughout the disease course (Fig. 1B, right). Similar results were also seen in rats with r-EAU induced by the transfer of R16-specific T cells (Fig. 1C). CD4\(^+\)CD25\(^+\) cells increased in the eye during resolution of the first acute attack of the disease (days 8–12) but did not change in the spleen (Fig. 1D).

Because CD25 expression is not a definitive marker for Tregs, we also assessed the expression of the transcription factor FoxP3, which determines differentiation of the regulatory phenotype, and distinguished Tregs from activated T-effector cells\(^{35,36}\) in relation to CD25 expression by ocular CD4\(^+\) cells. Most CD4\(^+\)CD25\(^+\) cells in the eye were found to express FoxP3 (Fig. 2A), at all times analyzed (Fig. 2B), in m-EAU and r-EAU, confirming that ocular CD25\(^+\) cells are regulatory T cells and not activated T-effector cells.
CD4\(^+\)CD25\(^+\) Tregs Derived from the Eye Are More Potent in m-EAU Than in r-EAU

To determine whether the inhibitory function of intraocular CD4\(^+\)CD25\(^+\) T cells on infiltrated effector T cells accounted for monophasic or recurrent EAU, we compared the ability of ocular Tregs from animals recovering from m-EAU or r-EAU to suppress the proliferation of R16 effector T cells in vitro. The CD4\(^+\)CD25\(^+\) Treg cells were derived from the eyes and spleens of rats with m-EAU (day 16 p.i.) and r-EAU (day 12 after transfer); CD4\(^+\)CD25\(^-\) T effector cells were derived from the spleens of m-EAU rats (9 days p.i.). The CD4\(^+\)CD25\(^-\) T effector cells proliferated in response to specific antigen, whereas CD25\(^+\) Tregs did not. Furthermore, the eye-derived CD4\(^+\)CD25\(^+\) Treg cells from the m-EAU rats completely abolished the proliferation of responder CD4\(^+\)CD25\(^-\) T cells at a Treg/T-responder ratio of as low as 1:10 (Fig. 3A), whereas the same eye-derived Treg cells from r-EAU rats (Fig. 3B) or the spleen of m-EAU rats (Fig. 3A) suppressed the proliferation of responder CD4\(^+\)CD25\(^-\) T cells at a Treg/T-responder ratio of only 1:4. Interestingly, there was a hierarchical potency of suppression by CD4\(^+\)CD25\(^+\) cells from different sources, with the m-EAU eye > r-EAU eye > m-EAU spleen (Fig. 3C). These results are consistent with the idea that CD4\(^+\)CD25\(^+\) Tregs in the eye are functionally activated and antigen specific.

Recurrent Uveitis Is Converted to m-EAU by the Transfer of Ocular CD4\(^+\)CD25\(^+\) Tregs from m-EAU

We demonstrated that the population of ocular CD4\(^+\)CD25\(^+\) Tregs in m-EAU was inhibitory at a higher dilution of cells than those from r-EAU in vitro. We sought to extend these observations in vivo by the induction of r-EAU, as previously described. These rats were then injected intraperitoneally on day 0 with 3 \times 10^5 ocular Treg cells prepared from m-EAU (day 16 p.i.) or r-EAU (day 12 after transfer) rats. Tregs from m-EAU rats significantly reduced disease severity and converted the disease...
the proportion of CD4⁺ cells in the eye producing IL-10 was small, there was an overall increase in the proportion of IL-10⁺ CD4⁺ cells over time (Fig. 5B) correlating with recovery in m-EAU, whereas the proportion of IL-10⁺ CD4⁺ cells in r-EAU did not significantly increase over time.

**AqH in m-EAU Enhanced the Inhibitory Function of CD⁴⁺CD₂⁵⁺ Tregs in r-EAU**

We then hypothesized that molecules present in the AqH in m-EAU contributed to the potent inhibitory effect of ocular Tregs. We incubated CD⁴⁺CD₂⁵⁺ Tregs from the eyes of r-EAU rats (12 days p.i.) with AqH from the eyes of either m-EAU (16 days p.i.) or r-EAU rats (12 days p.i.). As shown in Figure 6A, AqH from m-EAU rats, but not r-EAU rats, enhanced the inhibitory function of ocular Tregs from r-EAU rats in a dose-dependent manner.

IL-10 has been observed in the aqueous humor of human eyes with uveitis. To determine whether IL-10 is present in higher concentrations in the AqH of m-EAU rats than r-EAU rats and whether IL-10 influences the function of Tregs, we used ELISA to study IL-10 levels in the AqH. The AqH of recovering m-EAU rats contained high levels of IL-10, but little or no IL-10 was detected in the AqH of r-EAU rats (Fig. 6B). When IL-10 was added to the AqH of recovering r-EAU rats, the suppressive effect of CD⁴⁺CD₂⁵⁺ cells was significantly enhanced (Fig. 6C).

**DISCUSSION**

Understanding the mechanisms that mediate the natural resolution of monophasic uveitis may facilitate the design of optimal therapeutic strategies for recurrent uveitis. We found that the accumulation of CD⁴⁺CD₂⁵⁺ T regulatory cells in the eye correlated with the recovery phase of m-EAU. Moreover, transfer of small numbers of ocular CD⁴⁺CD₂⁵⁺ Treg cells from recovering m-EAU rats prevented recurrences in r-EAU recipients. Although there is extensive evidence for the important role of CD⁴⁺CD₂⁵⁺ Tregs in preventing spontaneous or induced autoimmune diseases, including EAU, it was unknown whether these cells mediated natural remission once inflammation was established. Our results demonstrated that CD⁴⁺CD₂⁵⁺ Tregs made a significant contribution to controlling an ongoing inflammatory response in the target organ. Dysregulation and malfunction of CD⁴⁺CD₂⁵⁺ Tregs in the eye may be an important factor in disease recurrence, persistence, and progression, though a number of other mechanisms may also contribute to the recurrence of inflammation.

The adoptive transfer of CD⁴⁺CD₂⁵⁺ Tregs into mice before immunization with IRBP is known to prevent the development of EAU. In contrast, CD₂⁵⁻ depleted wild-type and knockout mice immunized with IRBP show enhanced antigen-specific immunologic responses and severity of intraocular inflammation. Depletion of CD₂⁵⁺ cells before the induction of EAU may result in an increased expansion of pathogenic effector T cells. Additionally, the rate of recovery from EAU was markedly slow, suggesting that CD⁴⁺CD₂⁵⁺ cells may play an active role in mediating recovery from intraocular inflammation. Indeed, we observed that the adoptive transfer of ocular CD₂⁵⁺ Tregs from the recovery phase of m-EAU prevented the development of r-EAU (Fig. 4), confirming that CD₂⁵⁺ Tregs played a central role in controlling ongoing intraocular inflammation and in the prevention of recurrent autoimmune uveitis.

The number of CD⁴⁺CD₂⁵⁺ Tregs in the eye in EAU was significantly increased during the recovery phase (Figs. 1, 2). A relatively small number of these highly potent cells may be sufficient to begin downregulation of local intraocular in-

**FIGURE 5.** Proportions of CD⁴⁺ IL-10⁺ cells were higher in the eyes of m-EAU than r-EAU rats. (A) Representative plots from ocular infiltrating cells of m-EAU rats stained with mAbs for CD4 and isotype control (left) and CD4/IL-10 (right). Cells were harvested on day 16 and stimulated in vitro with PMA/ionomycin. (B) Ocular infiltrated cells were harvested from rats with m-EAU and r-EAU at the peak and recovery phases of disease (4 rats/day), stimulated with PMA/ionomycin, and analyzed for the expression of CD4 and intracellular IL-10. The percentage of IL-10⁺CD⁴⁺ T cells was calculated and is representative of two experiments.

**IL-10 Produced by CD4 Cells Is Increased in m-EAU Compared with r-EAU**

The inhibitory function of Tregs occurs through IL-10, which is likely to be important during recovery from EAU. Thus, the production of IL-10 by lymphoid cells in the eye of m-EAU and r-EAU was compared to determine whether the amount of IL-10 produced contributed to the function of Treg. CD⁴⁺ cells were found to be major producers of IL-10 (Fig. 5A). Although pattern in recipients to monophasic, whereas the same number of ocular Tregs from r-EAU rats had a less suppressive effect (Fig. 4A). These results suggested that r-EAU is at least partially attributed to the low inhibitory efficiency of ocular CD⁴⁺CD₂⁵⁺ Tregs generated in the r-EAU model. Histologic examination on day 8 showed that although infiltration of inflammatory cells was seen in the anterior segment in all three groups (data not shown), only limited retinal damage was seen in the eyes of rats treated with Tregs from m-EAU rats, in contrast to the other two groups (Fig. 4B). Furthermore, R16-specific splenic T cells on day 8 from the rats treated with ocular CD⁴⁺CD₂⁵⁺ m-EAU Tregs responded poorly to in vitro stimulation with R16 (Fig. 4C). Interestingly, spleen cells recovered on day 30 from rats treated with ocular Tregs from m-EAU animals did not (Fig. 4D). These results supported the conclusion that ocular Tregs from m-EAU rats inhibited R16-specific effector T cells in vivo, as well as in vitro.

Pattern in recipients to monophasic, whereas the same number of ocular Tregs from r-EAU rats had a less suppressive effect (Fig. 4A). These results suggested that r-EAU is at least partially attributed to the low inhibitory efficiency of ocular CD⁴⁺CD₂⁵⁺ Tregs generated in the r-EAU model. Histologic examination on day 8 showed that although infiltration of inflammatory cells was seen in the anterior segment in all three groups (data not shown), only limited retinal damage was seen in the eyes of rats treated with Tregs from m-EAU rats, in contrast to the other two groups (Fig. 4B). Furthermore, R16-specific splenic T cells on day 8 from the rats treated with ocular CD⁴⁺CD₂⁵⁺ m-EAU Tregs responded poorly to in vitro stimulation with R16 (Fig. 4C). Interestingly, spleen cells recovered on day 30 from rats treated with ocular Tregs from m-EAU animals did not (Fig. 4D). These results supported the conclusion that ocular Tregs from m-EAU rats inhibited R16-specific effector T cells in vivo, as well as in vitro.

Pattern in recipients to monophasic, whereas the same number of ocular Tregs from r-EAU rats had a less suppressive effect (Fig. 4A). These results suggested that r-EAU is at least partially attributed to the low inhibitory efficiency of ocular CD⁴⁺CD₂⁵⁺ Tregs generated in the r-EAU model. Histologic examination on day 8 showed that although infiltration of inflammatory cells was seen in the anterior segment in all three groups (data not shown), only limited retinal damage was seen in the eyes of rats treated with Tregs from m-EAU rats, in contrast to the other two groups (Fig. 4B). Furthermore, R16-specific splenic T cells on day 8 from the rats treated with ocular CD⁴⁺CD₂⁵⁺ m-EAU Tregs responded poorly to in vitro stimulation with R16 (Fig. 4C). Interestingly, spleen cells recovered on day 30 from rats treated with ocular Tregs from m-EAU animals did not (Fig. 4D). These results supported the conclusion that ocular Tregs from m-EAU rats inhibited R16-specific effector T cells in vivo, as well as in vitro.

Pattern in recipients to monophasic, whereas the same number of ocular Tregs from r-EAU rats had a less suppressive effect (Fig. 4A). These results suggested that r-EAU is at least partially attributed to the low inhibitory efficiency of ocular CD⁴⁺CD₂⁵⁺ Tregs generated in the r-EAU model. Histologic examination on day 8 showed that although infiltration of inflammatory cells was seen in the anterior segment in all three groups (data not shown), only limited retinal damage was seen in the eyes of rats treated with Tregs from m-EAU rats, in contrast to the other two groups (Fig. 4B). Furthermore, R16-specific splenic T cells on day 8 from the rats treated with ocular CD⁴⁺CD₂⁵⁺ m-EAU Tregs responded poorly to in vitro stimulation with R16 (Fig. 4C). Interestingly, spleen cells recovered on day 30 from rats treated with ocular Tregs from m-EAU animals did not (Fig. 4D). These results supported the conclusion that ocular Tregs from m-EAU rats inhibited R16-specific effector T cells in vivo, as well as in vitro.
flammation, and the increased proportion seen in the later phase of the disease may reflect their continued recruitment/expansion in the eye. Although Tregs were initially described in in vitro studies as hypoproliferative, it is now clear that these cells can be expanded in vivo by antigen, particularly in the presence of inflammatory signals such as up-regulated costimulatory molecules on activated APCs and dendritic cells. Tregs that have recently been activated or expanded in vitro are more potent than resting Tregs. We demonstrated that CD4<sup>+</sup>CD25<sup>+</sup> T cells in the eye are more potent as suppressors in vitro (Fig. 3) than those in the spleen. Moreover, very low numbers of CD4<sup>+</sup>CD25<sup>+</sup> T cells from the eye were able to transfer protection to naïve recipients (Fig. 4), whereas the same number of CD4<sup>+</sup>CD25<sup>+</sup> T cells from the spleen had no effect (Ke Y, Shao H, unpublished observation, 2007).

The different protocols used to induce m-EAU and r-EAU may result in different Treg subsets and Tregs with strong and weak antigen specificity. We have observed that CD4<sup>+</sup>CD25<sup>+</sup> Tregs from naïve rats also have suppressive activity in vitro (data not shown). In addition, the regulatory T cells isolated from IRBP-induced EAU were more inhibitory for uveitogenic T cells than for MOG-induced encephalitogenic T cells. Thus, we believe that naive and inducible Tregs exist in m-EAU and r-EAU. Unfortunately, because of technical limitations, the differences between these Treg populations cannot be discerned at this time.

We observed that IL-10 was important for the regulation of EAU by Tregs. CD4<sup>+</sup> cells were the major source of IL-10 in the eye (Fig. 5A), and IL-10 production is known to be crucial for the resolution of intraocular inflammation. Treg cells may also produce TGF-β; the production and action of these two cyto-
kines are interrelated and are likely to involve positive feedback loops in which IL-10 enhances the expression of TGF-β and vice versa. IL-10 may act locally at the site of inflammation, whereas TGF-β seems to have a more systemic effect on the immune response. Because no anti-rat TGF-β antibody is available to detect this cytokine by flow cytometry, we focused only on IL-10 in this study.

Furthermore, the observed inability of ocular Tregs from r-EAU to protect against subsequent episodes of intraocular inflammation could not be explained by a subpopulation of CD4−CD25+ effector T cells because most CD4+CD25+ cells in the eye were found to express FoxP3 (Fig. 2A).

The strong inhibitory activity of ocular Tregs was dependent on the AqH within the eye. Although a similar percentage of ocular Tregs was seen during recovery from the first acute episode of m-EAU and r-EAU, the inhibitory function of these cells on effector R16-specific T cells was different. Those from m-EAU rats were more potent inhibitors (Fig. 6), presumably because of a difference in the amount of regulatory factors such as IL-10, TGF-β, and α-melanocyte stimulating hormone49 in the AqH. Interestingly, the weaker suppressive activity of CD4+CD25+ Tregs from r-EAU rats was enhanced by incubation with AqH from m-EAU rats. It is known that many immunoregulatory factors in AqH protect those from m-EAU rats were more potent inhibitors (Fig. 6), presumably because of a difference in the amount of regulatory factors such as IL-10, TGF-β, and α-melanocyte stimulating hormone in the AqH. Interestingly, the weaker suppressive activity of CD4+CD25+ Tregs in r-EAU was enhanced by incubation with AqH from m-EAU rats. It is known that many immunoregulatory factors in AqH protect the eye from inflammation. AqH not only suppresses inflammation but also suppresses the activation of Th1 cells, it promotes the induction of CD4+CD25+ Treg cells.50,51 Our studies provide additional evidence that factors in the AqH contribute to the functional potency of CD4+CD25+ Treg cells, thus leading to different clinical presentations of autoimmune uveitis. Better understanding of the mechanism(s) by which Treg cells are influenced by the local microenvironment may identify novel methods of immune regulation.

Despite the weak inhibitory activity of ocular Tregs during recovery from the first acute episode of r-EAU, remission still occurred. It seems that the weak inhibition of ocular Tregs temporarily reduced the pathogenic effect of effector T cells, but, given that uveitis recurred, they did not induce anergy or elimination of effector T cells. In contrast, the anergy or elimination of effector T cells was seen in rats treated with ocular Tregs of m-EAU animals because few (day 8 after transfer; Fig. 4C) or no (day 30 after transfer; data not shown) R16-specific responder T cells were seen in the in vitro proliferative response assay. Indeed, no uveitis was induced by T cells derived from the rats treated with ocular Tregs from m-EAU animals because of the anergy or elimination of R16 effector T cells (Fig. 4D). Therefore, CD4−CD25+ T regulatory cells within the eye played an active and central role in modulating recovery from the first episode of acute EAU and in preventing the development of recurrent or chronic disease.

In conclusion, our data showed that CD4−CD25+ Treg cells derived from the eye during recovery from m-EAU have strong suppressor activity and are involved in the remission of intraocular inflammation. A similar effect of CD4−CD25+ T cells has been shown in other disease models, such as colitis, early-onset diabetes, and experimental autoimmune encephalitis.53 Understanding the physiological mechanisms (e.g., self-antigen, costimulatory molecules on APCs, cytokines) that drive the expansion and recruitment of Tregs in EAU may provide an effective therapy for autoimmune conditions, particularly in diseases with a relapsing-remitting course such as autoimmune uveitis.

References


